Amphiregulin and epiregulin expression in neoplastic and inflammatory lesions in the colon

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 105-110

  Nishimura, Takashi ^a   Andoh, Akira ^a   Inatomi, Osamu ^a   Shioya, Makoto ^a   Yagi, Yuhki ^a   Tsujikawa, Tomoyuki ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Epidermal growth factor; Inflammatory bowel disease; Repair

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN;

ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; COLITIS; COLON ADENOMA; COLON CARCINOMA; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; CROHN DISEASE; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; PRIORITY JOURNAL; TISSUE REPAIR; TUMOR GROWTH; ULCERATIVE COLITIS;

EID: 38749145843     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.105     Document Type: Article

References (24)

1. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
2. Chowdhury A, Fukuda R and Fukumoto S: Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol 31: 353-360, 1996.
3. Tarnawski AS and Jones MK: The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 27: S12-S20, 1998.
4. Beck PL and Podolsky DK: Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 5: 44-60, 1999.
5. Shoyab M, McDonald VL, Bradley JG and Todaro GJ: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85: 6528-6532, 1988.
6. Plowman GD, Green JM, McDonald VL, et al: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969-1981, 1990.
7. Castillo J, Erroba E, Perugorria MK, et al: Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66: 6129-6138, 2006.
8. Normanno N, Selvam MP, Qi CF, et al: Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci USA 91: 2790-2794, 1994.
9. Piepkorn M, Lo C and Plowman G: Amphiregulin-dependent proliferation of cultured human keratinocytes: autocrine growth, the effects of exogenous recombinant cytokine and apparent requirement for heparin-like glycosaminoglycans. J Cell Physiol 159: 114-120, 1994.
10. Chu EK, Foley JS, Cheng J, Patel AS, Drazen JM and Tschumperlin DJ: Bronchial epithelial compression regulates epidermal growth factor receptor family ligand expression in an autocrine manner. Am J Respir Cell Mol Biol 32: 373-380, 2005.
11. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS and Stromberg K: Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol 118: 741-751, 1992.
12. Damstrup L, Kuwada SK, Dempsey PJ, et al: Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 80: 1012-1019, 1999.
13. Beales IL: Gastrin and interleukin-1β stimulate growth factor secretion from cultured rabbit gastric parietal cells. Life Sci 75: 2983-2995, 2004.
14. Toyoda H, Komurasaki T, Uchida D, et al: Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 270: 7495-7500, 1995.
15. Shirakata Y, Komurasaki T, Toyoda H, et al: Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 275: 5748-5753, 2000.
16. Takahashi M, Hayashi K, Yoshida K, et al: Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 108: 2524-2529, 2003.
17. Lee D, Pearsall RS, Das S, Dey SK, Godfrey VL and Threadgill DW: Epiregulin is not essential for the development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 24: 8907-8916, 2004.
18. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) vs. sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82-86, 1989.
19. Best WR, Becktel JM and Singleton JW: Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 77: 843-846, 1979.
20. Fujino S, Andoh A, Bamba S, et al: Increased expression of interleukin-17 in inflammatory bowel disease. Gut 52: 65-70, 2003.
21. Inatomi O, Andoh A, Yagi Y, Bamba S, Tsujikawa T and Fujiyama Y: Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med 18: 497-503, 2006.
22. Baba I, Shirasawa S, Iwamoto R, et al: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signalling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000.
23. Egger B, Procaccino F, Lakshmanan J, et al: Mice lacking transforming growth factor α have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 113: 825-832, 1997.
24. Fichera A, Little N, Jagadeeswaran S, et al: Epidermal growth factor receptor signalling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 67: 827-835, 2007.